4//SEC Filing
Skovronsky Daniel 4
Accession 0000059478-25-000039
CIK 0000059478other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:15 PM ET
Size
13.6 KB
Accession
0000059478-25-000039
Insider Transaction Report
Form 4
Skovronsky Daniel
EVP, CSO & Pres. LRL & LLY Imm
Transactions
- Sale
Common Stock
2025-02-10$862.69/sh−3,950$3,407,626→ 118,938.36 total - Sale
Common Stock
2025-02-10$863.97/sh−340$293,750→ 118,598.36 total - Sale
Common Stock
2025-02-10$865.76/sh−710$614,690→ 117,888.36 total - Award
Common Stock
2025-02-10$868.88/sh+18,771.752$16,310,400→ 136,660.112 total - Award
Restricted Stock Unit
2025-02-10+12,684→ 12,684 totalFrom: 2026-02-01Exp: 2026-02-01→ Common Stock (12,684 underlying)
Holdings
- 72,359(indirect: By Trust)
Common Stock
- 3,257(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F4]Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Documents
Issuer
ELI LILLY & Co
CIK 0000059478
Entity typeother
Related Parties
1- filerCIK 0001741474
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:15 PM ET
- Size
- 13.6 KB